TL;DR. A “poison pill” — formally, a shareholder rights plan — is a corporate bylaw that lets a company flood the market with cheap new shares if any single investor crosses a set ownership threshold, typically 10–20%. The mechanic dilutes the would-be acquirer’s stake so severely that a hostile takeover becomes prohibitively expensive. Invented by attorney Martin Lipton in 1982 and blessed by the Delaware Supreme Court in Moran v. Household International (1985), the pill is the most-used takeover defense in U.S. corporate law.
What a poison pill actually is
A poison pill is not a single document you sign at closing. It is a contingent right issued to every existing shareholder in the form of a dividend. Each right sits dormant, worth nothing, until an “acquiring person” quietly crosses a pre-defined ownership threshold — the trigger. Once triggered, the rights become exercisable, and every shareholder except the acquirer can buy new shares (or shares in the merged entity) at a steep discount, usually 50% off market.
The math is designed to be brutal. If the acquirer holds 15% of the company and every other shareholder doubles their position at half price, the acquirer’s slice shrinks toward 7–8% overnight. To match their old stake, the raider would have to spend billions more — typically enough to make the bid uneconomic and force them to the negotiating table.
Flip-in vs flip-over: two ways the pill fires
Modern rights plans usually contain both features, though the flip-in does most of the work in practice.
- Flip-in. The classic mechanic described above. Everyone except the triggering shareholder gets to buy new shares at a discount. The bidder cannot participate, so their percentage stake collapses.
- Flip-over. Kicks in after a merger has closed against the target’s wishes. Former target shareholders can buy shares of the acquirer at a discount, punishing the acquirer’s own balance sheet post-deal.
Think of it this way: the flip-in makes the bid too expensive to close; the flip-over makes closing a hollow victory.
A simple worked example
Assume a company has 100 million shares outstanding at $50 each ($5B market cap) and a pill with a 15% trigger and a 50%-discount flip-in right.
Raider “R” quietly buys 15% (15M shares) at a $52 average, spending $780M. The pill triggers. Every other shareholder — the 85M shares R does not own — now has the right to buy one new share for every share held at $25 (half of the $50 market price). If they all exercise, the company issues 85M new shares.
Share count jumps from 100M to 185M. R still owns 15M shares, but now that stake represents just ~8.1% of the company, not 15%. To rebuild a 15% stake, R would need to buy roughly 13M additional shares in the open market — a purchase that itself would trigger further dilution because R is still the acquiring person under the plan. The economic result: the raider is stuck. That is the entire point.
Where the pill came from: Lipton, Moran, and the M&A boom of the 1980s
The poison pill did not exist before 1982. It was designed by Martin Lipton, co-founder of the New York law firm Wachtell, Lipton, Rosen & Katz, in response to the wave of tender-based hostile takeovers sweeping American boardrooms — T. Boone Pickens, Carl Icahn, and the corporate raiders of the leveraged-buyout era. Lipton’s innovation was so consequential that Stanford legal scholar Ronald Gilson called it “the most important innovation in corporate law since Samuel Calvin Tate Dodd invented the trust.”
The pill’s legal legitimacy was settled three years later. In Moran v. Household International, decided by the Delaware Supreme Court on November 19, 1985, the court upheld a board’s right to adopt a shareholder rights plan prophylactically — before any specific bid was on the table — as a valid exercise of business judgment. Because roughly two-thirds of publicly traded U.S. companies are incorporated in Delaware, that ruling effectively made the pill national policy.
The historical record: five landmark pills
These are among the most-cited real-world uses of the mechanism — whether the bid succeeded, failed, or was renegotiated at a much higher price.
| Target | Year adopted | Bidder / activist | Outcome |
|---|---|---|---|
| Household International | 1984 | Preemptive (no active bidder) | Upheld by Delaware Supreme Court in Moran (1985), setting the template. |
| Yahoo! | 2001 | Microsoft ($44.6B bid, Feb 2008) | Pill in place when Microsoft bid; Microsoft withdrew May 2008. |
| PeopleSoft | 2003 | Oracle | Pill and “customer assurance” clauses delayed deal ~18 months; Oracle eventually closed at $10.3B (Dec 2004). |
| Airgas | 2010 | Air Products ($5.9B tender offer) | Delaware Chancery upheld the pill; Air Products abandoned the bid Feb 15, 2011. |
| April 15, 2022 | Elon Musk ($54.20/share, ~$43B) | Pill forced Musk to negotiate; board accepted the same $54.20/share on Apr 25; deal closed Oct 27, 2022 at ~$44B. |
Trigger thresholds and design choices
Every pill is different, but a handful of design levers show up in almost every plan:
- Trigger percentage. Historically 10–20% of shares outstanding. Pills aimed at activist investors (rather than full-blown acquirers) tend to sit at the lower end — Twitter’s 2022 plan and many “NOL protective” pills use thresholds as low as 4.99% to protect deferred tax assets.
- Sunset date. Most modern pills auto-expire in one year unless renewed. Twitter’s April 2022 plan, for example, was set to expire on April 14, 2023. Short sunsets soften the corporate-governance criticism from proxy advisors like ISS and Glass Lewis.
- “Qualified offer” carve-out. Some plans exempt fully financed, all-cash tender offers that stay open long enough for shareholders to vote. This defuses the accusation that the pill entrenches the board against value-creating bids.
- Redemption right. Boards can pull the pill at any time for a nominal price (often $0.001 per right). That is the leverage: the pill is a tool for negotiation, not a permanent moat.
Common mistakes and where pills break down
- A pill is not a permanent shield. Delaware courts still apply the enhanced Unocal scrutiny standard: the board must show the pill is a reasonable response to a real threat. In The Williams Companies Stockholder Litigation (2021), the Delaware Court of Chancery struck down a pill it found overbroad — a reminder that even well-intentioned plans can fail judicial review.
- The pill does not stop a proxy fight. Bidders can (and do) run alternative director slates to replace the board and redeem the pill themselves. That is how many “successful” hostile bids ultimately close — through the boardroom, not the tender offer.
- Activists price it in. Because pills are so common, most activist campaigns assume one will be adopted and structure their approach (13D disclosure timing, wolf-pack coordination, board-nominee slates) accordingly.
- Governance backlash. A pill adopted without shareholder ratification can trigger negative recommendations from ISS on director elections, potentially costing directors their seats even if the pill “works.”
Related concepts & what to learn next
- Leveraged buyouts — the acquisition structure a pill is often designed to block.
- IPO lockups — another example of contract-driven share supply management.
- Unocal Corp. v. Mesa Petroleum Co. (1985) — the Delaware standard for reviewing defensive measures generally.
- Revlon v. MacAndrews & Forbes (1986) — when a sale becomes inevitable, the board’s duty shifts to getting the highest price. Pills cannot override Revlon duties.
Sources
- U.S. Securities and Exchange Commission — Poison Pills (investor bulletin)
- Shareholder Rights Plan — Wikipedia summary of mechanics and case law
- Moran v. Household International (Del. 1985)
- Martin Lipton — biography and invention of the rights plan (1982)
- Airgas — 2010–2011 defense against Air Products
- Acquisition of Twitter by Elon Musk — 2022 rights plan
- Yahoo! — Microsoft’s $44.6B bid in 2008
Disclosure: This article was produced with AI assistance and reviewed before publication. It is for informational purposes only and is not investment advice.